1. Introduction {#s0005}
===============

Primary central nervous system (CNS) lymphoma is a rare CNS disease in immunocompetent patients, which accounts for approximately 2% of all primary CNS tumors([@bb0120]). The definitive diagnosis of CNS lymphoma is essential due to the differences in strategies for surgery, chemotherapy and radiotherapy between CNS lymphomas and other malignant CNS tumors, such as glioblastoma multiforme (GBM)([@bb0030]; [@bb0080]). Although magnetic resonance imaging (MRI) is frequently applied for the initial evaluation of CNS neoplasms, the radiological differentiation of lymphoma from GBM remains difficult (i.e., lymphoma and GBM can both present with a solid enhanced pattern without visible necrosis on T1-weighted contrast enhanced images).

^18^F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is an alternative imaging modality that has been utilized for the assessment of CNS disorders([@bb0055]). CNS lymphomas usually have a relatively high tumor cell density and increased glucose metabolism, resulting in an increased standardized uptake value (SUV)([@bb0050]; [@bb0045]; [@bb0035]). Although few studies have investigated the role of ^18^F-FDG-PET for distinguishing CNS lymphoma from GBM([@bb0170]; [@bb0130]; [@bb0185]), the parameters involved in these studies have been mostly restricted to specific features, such as the maximum SUV (SUVmax) and tumor-to-normal contralateral cortex activity (T/N) ratio, which can hardly display the characteristics of the whole tumor.

Radiomics is a recent emerging technique that extracts high-throughput imaging features to quantitatively describe the characteristics of a tumor, and to investigate the relationship between radiomics features and tumor phenotype([@bb0075]; [@bb0085]). Radiomics based on multimodal MRI images can detect the heterogeneity within brain tumors and has been widely utilized in the noninvasive prediction of clinical manifestation([@bb0095]), genetic characteristics([@bb0090]) and patient prognosis([@bb0010]; [@bb0015]; [@bb0020]; [@bb0100]). The ^18^F-FDG-PET-based radiomics approach extracts conventional and textural features and has been successfully utilized for differential diagnosis, treatment response prediction, mutation detection of lung([@bb0180]), cervical([@bb0145]), and nasopharyngeal cancer([@bb0110]). Although previous studies have demonstrated the differential MRI characteristics of CNS lymphoma and GBM taking advantage of the radiomics approach([@bb0175]; [@bb0005]; [@bb0070]; [@bb0040]; [@bb0140]; [@bb0060]), limited studies have focused on differentiation of these two cancers using ^18^F-FDG-PET radiomics. This study retrospectively investigates the imaging characteristics of CNS lymphoma and GBM on ^18^F-FDG-PET using a radiomics approach, and selects distinguishable radiomics features for the differential diagnosis of CNS lymphoma from GBM noninvasively.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

This study retrospectively enrolled 77 patients (24 with CNS lymphoma and 53 with GBM) treated at Peking Union Medical College Hospital between January 2010 and October 2018. The inclusion criteria were as follow: 1) age ≥ 18 years old; 2) underwent surgical resection or biopsy with pathology confirmed primary CNS lymphoma or GBM; 3) had a preoperative ^18^F-FDG-PET/CT scan of the brain. The exclusion criteria were as follow: 1) a history of brain tumors; 2) suspected or confirmed peripheral lymphomas; 3) treated with corticosteroids, radiotherapy or chemotherapy before surgery; 4) diabetes mellitus (blood glucose ≥10 mmol/L); 5) iatrogenic or disease-related immunosuppression. The study has been approved by the institutional review board, and all patients signed an informed consent form.

2.2. ^18^F-FDG-PET/CT acquisition and preprocessing {#s0020}
---------------------------------------------------

All patients were required to fast for at least 4 h before ^18^F-FDG-PET/CT scans were performed. The ^18^F-FDG was produced on-site using RDS-111 Cyclotron (CTI, Knoxville, TN, USA). A dose of 5.55 MBq (0.15 mCi) ^18^F-FDG per kilogram of body weight was administered intravenously under standardized conditions (in a quiet, dimly lit room with the patient\'s eyes closed). The scans were obtained 40--60 min after ^18^F-FDG administration on a Biograph 64 TruePoint TrueV PET/CT system (Siemens Medical Solutions, Erlangen, Germany), which permitted 3-dimensional acquisition with interslice spacing of 3 mm. Images acquired from the PET/CT system were calibrated on the PET/CT workstation and the DICOM images underwent an interpolation with the workstation which doubled the physical resolution.

2.3. Image segmentation {#s0025}
-----------------------

Tumors were manually segmented by two experienced neurosurgeons who were blinded to the patients\' information, and three-dimensional regions of interest (ROIs) were delimited on ^18^F-FDG-PET images using the ITK-SNAP software (<http://www.itksnap.org/pmwiki/pmwiki.php>). A senior nuclear medical scientist subsequently reevaluated the segmented lesions. In cases of discrepancies \<5% between the two neurosurgeons, the final ROI was defined as the overlapping area of their delineations, while in cases of discrepancies \>5% between the two neurosurgeons, the nuclear medical scientist made the final decision. An example of the image segmentation is displayed in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Example of the three-dimensional tumor segmentation (red area) and marginal expansion (green area). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1

2.4. Postprocessing and feature extraction {#s0030}
------------------------------------------

The SUV value of each pixel was calculated with the following formula([@bb0115]; [@bb0125]):$${SUV} = \frac{\mathit{Measure\ Activity}_{({\mathit{Bq}/\mathit{ml}})}}{\frac{\mathit{Injected\ Dose}_{(\mathit{mCi})}}{\mathit{Decay\ Factor} \times \mathit{Body}\ We\mathit{ight}_{(g)}}}$$

The calculation of SUV was carried out on an in-house software constructed with SimpleITK (<http://www.simpleitk.org>)([@bb0105]) and pydicom (<https://github.com/pydicom/pydicom>). The decay factor was computed with the half-life of the tracer and the time elapsed between the collection and the injection. All of the parameters were integrated in the DICOM metadata. The algorithm was adapted from the suggested vendor neutral pseudocode by the QIBA FDG-PET/CT Standardized Uptake Value (SUV) Technical Subcommittee([@bb0115]; [@bb0125]).

Three groups of maps, namely, an SUV map, an SUV map with each pixel divided by the normal contralateral cortex (ncc) activity (SUV/ncc map), and an SUV map with each pixel divided by the normal brain mean (nbm) activity (SUV/nbm map), were generated. During the creation of the SUV/nbm map, the skulls were stripped on the CT series and directly resampled with the nearest neighbor algorithm to the PET series. Features of these three groups of maps were extracted separately with identical parameters.

No further normalization of the brightness level was performed on processed maps. No resampling was carried out in order to maintain a higher resolution. Considering the dynamic range of the SUV maps, the bin width for matrices statistics was set to 1. A total of 107 radiomics features were extracted from the ROIs of each SUV map with pyradiomics version 2.1.0 (an open source package covered by the 3-clause BSD License, accessed at <http://www.radiomics.io/>)([@bb0150]). Radiomics features were defined and calculated according to the formulas from pyradiomics (explanation document available at <http://pyradiomics.readthedocs.io/en/2.1.0/features.html>), and most of which are in accordance with features defined by Imaging Biomarker Standardization Initiative([@bb0190]). The extracted features are summarized in Supplementary material 1.

2.5. Feature evaluation {#s0035}
-----------------------

Conventional features including SUVmax, T/N ratio, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated and evaluated their performance in differentiating lymphoma and GBM.

The Mann--Whitney *U* test was performed to test whether a radiomics feature was significantly different between GBM and lymphoma. The discrimination performance of each radiomics feature was evaluated by the area under the curve (AUC) of the receiver operating characteristic (ROC) curve([@bb0135]), whose classifier is a single feature threshold-based simple classifier (a decision tree classifier with one decision node). The AUC of the feature 'First order_Maximum' (also known as SUVmax in nonradiomics studies) was used as the threshold for assessing whether a feature was more discriminative than SUVmax.

2.6. Marginal adjustment {#s0040}
------------------------

To evaluate the robustness of the features and the impact of ROI quality, the edge of the original ROI was expanded with a radius of 2 voxels in all spatial directions (2 mm in X-Y plane and 3 mm in the Z axis) to generate an ROI after marginal adjustment (ROIma). An example of the marginal adjustment is displayed in [Fig. 1](#f0005){ref-type="fig"}. Radiomics features from the SUV map, SUV/ncc map, and SUV/nbm map from the ROIma were also extracted. Intraclass correlation coefficient (ICC) between the features extracted from the ROI and ROIma in the SUV map were calculated using the variance components from a one-way ANOVA, and features were considered stable if ICC \> 0.50 ([@bb0065]).

2.7. Analysis of solid metabolic tumors {#s0045}
---------------------------------------

A solid metabolic tumor was defined as a lesion without a significant necrosis or cysts inside the ROI, which is known as atypical glioblastoma among GBM patients ([@bb0140]). Solid metabolic tumors for the whole patient group were manually selected, and their radiomics features from the abovementioned 3 radiomics maps (SUV map, SUV/ncc map and SUV/nbm map) with the two ROIs (initial ROI and ROIma) were and evaluated separately.

2.8. Feature selection and performance evaluation {#s0050}
-------------------------------------------------

Radiomics features were selected to differentiate lymphoma from GBM if: 1) significantly different between GBM and lymphoma (*p* \< 0.05); 2) relatively stable after marginal adjustment (ICC \> 0.50); 3) performed better than 'First order_Maximum' in all 12 situations (in the SUV map, SUV/ncc map and SUV/nbm map with the initial ROI and ROIma, and in the whole population and in solid metabolic tumors). The threshold values of the selected features were calculated. The accuracy, sensitivity, specificity, precision rate, and recall rate of the selected features in the whole population were also calculated to evaluate the differential performances.

2.9. Feature validation with machine learning approach {#s0055}
------------------------------------------------------

AUC values with 5-fold cross validation were calculated for the selected radiomics features under 6 situations with the whole population (in the SUV map, SUV/ncc map and SUV/nbm map, with the initial ROI and ROIma) to better validate the prediction performances. Randomized grouping of the cross-validation was performed, and a single subgroup is retained as the validation cohort for testing the model while the remaining 4 subgroups are used as training cohort. The grouping was excluded if any of the subgroup contains only one type of tumor. The average AUC value of the 5-rounds of cross-validation (cross-validated AUC) was calculated to reflect the performance of the selected radiomics features.

2.10. Radiomics map generation and differentiation presentation {#s0060}
---------------------------------------------------------------

The radiomics maps were produced with a 21\*21 square mask moving through each pixel in a selected 336\*336 pixel layer, making the radiomics map to have 316\*316 pixels. At each possible position, a set of radiomics features was calculated with the moving mask and reflected regional radiomics characteristics of the image. Radiomics maps were further utilized to present the diversities in lymphoma and GBM patients.

2.11. Statistical analysis {#s0065}
--------------------------

All statistical analyses were performed with R 3.5.1 (<https://www.r-project.org>), scikit-learn 0.20.1 (<https://scikit-learn.org>) and Python 3.6.6 (<https://www.python.org>). The analysis was performed with a normal computer (Intel Core i9-7940× CPU @ 3.1 GHz base frequency, 64 GB RAM, Windows 10).

3. Results {#s0070}
==========

3.1. Patient characteristics {#s0075}
----------------------------

The baseline characteristics of the 24 CNS lymphoma patients and 53 GBM patients are demonstrated in [Table 1](#t0005){ref-type="table"}. There were significant differences in sex, lesion number, metabolic pattern, SUVmax, T/N ratio and MTV between two groups, while the variation in age and TLG did not reach statistical significance. The pathological information of the included patients was also acquired. All of the 24 lymphoma patients were diagnosed with diffuse large B cell lymphoma, and 2 (3.8%), 48 (90.6%), and 3 (5.6%) of the GBM patients had molecular features of isocitrate dehydrogenase (IDH)-mutant, IDH-wildtype, and IDH-unknown, respectively. There were 21 (87.5%) lymphoma patients and 21 (39.6%) GBM patients with a solid metabolic tumor pattern, and these patients were included in the analysis for solid tumors.Table 1Characteristics of the lymphoma and glioblastoma patients.Table 1CharacteristicsLymphomaGlioblastoma*P*-valueSex0.045 Male11 (45.8%)37 (69.8%) Female13 (54.2%)16 (30.2%)Age (mean ± SD)58.83 ± 12.6753.42 ± 14.830.125SUVmax (mean ± SD)23.76 ± 8.2613.50 ± 4.37\< 0.001T/N ratio (mean ± SD)5.77 ± 1.904.13 ± 1.370.001MTV (mean ± SD)23.06 ± 24.0744.50 ± 39.400.004TLG (mean ± SD)565.24 ± 539.03385.89 ± 404.120.109Lesion number0.007 Single16 (66.7%)52 (98.1%) Multiple8 (33.3%)1 (1.9%)Metabolic pattern\< 0.001 Solid21 (87.5%)21 (39.6%) Cystic3 (12.5%)32 (60.4%)[^2]

3.2. Differential performance of conventional features {#s0080}
------------------------------------------------------

SUVmax, T/N ratio and MTV and TLG were the conventional quantitative features that been evaluated, and they reached the AUC of 0.943, 0.870, 0.707 and 0.608, accuracy of 0.883, 0.844, 0.662 and 0.701 in differentiating CNS lymphoma from GBM, respectively.

3.3. Radiomics feature evaluation of the whole population {#s0085}
---------------------------------------------------------

The heat map of the 107 radiomics features from the SUV map is shown in [Fig. 2](#f0010){ref-type="fig"}(A). Among the features extracted from each SUV map, 95 (88.8%), 89 (83.2%), and 90 (84.1%) features (for the SUV map, SUV/ncc map, SUV/nbm map, respectively) were significantly different (*p* \< 0.05) between CNS lymphoma and GBM patients, with AUCs for differentiating CNS lymphoma and GBM ranging from 0.644 to 0.999. Most radiomics features from the SUV map demonstrated a similar or slightly higher AUC value compared with features from the SUV/nbm map, and features from both of these maps displayed moderately higher AUC values than features from the SUV/ncc map. The ICC of the 107 features extracted from the SUV map ranged from 0.01 to 0.84 with a mean value of 0.43, and 46 (43.0%) were relatively stable (ICC \> 0.50) despite marginal adjustment. The statistical properties and differentiation performance of the radiomics features in the whole population are detailed in [Supplementary material 2](#ec0010){ref-type="supplementary-material"}.

The radiomics feature 'First order_Maximum' showed an AUC of 0.943, 0.870, and 0.934 when differentiating CNS lymphoma and GBM in the SUV map, SUV/ncc map, and SUV/nbm map, respectively. Thirty-one features from the SUV map displayed better AUCs than 'First order_Maximum', and there were 33 features after ncc or nbm correction. The heat map of the 31 discriminating features from the SUV map is shown in [Fig. 2](#f0010){ref-type="fig"}(B). Features that had better differentiation performance than 'First order_Maximum' in all three SUV maps are shown in [Fig. 3](#f0015){ref-type="fig"}.Fig. 2Heat maps of all radiomics features in the whole population (A), the 31 distinguishing features in the whole population (B), and the 25 distinguishing features in the solid metabolic tumors (C). Heat maps were clustered by pathological information, with the blue column on the left indicating lymphoma patients and the yellow column indicating glioblastoma patients. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2Fig. 3Name and performance of the features that had better differentiation performance than 'First order_Maximum' in any of the 12 situations. The performances of 'First order_Maximum' are labeled in green at the bottom of the figure, and features that outperformed 'First order_Maximum' are labeled in red, with a stronger color indicating higher AUC values. Features that performed worse than 'First order_Maximum' are labeled blue. Abbreviations: T, tumor; ncc, calibrated by the normal contralateral cortex activity; nbm, calibrated by the normal brain mean activity; ma, marginal adjustment; sm, solid metabolic. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3

There was a slight increase or decrease in the performance of each radiomics feature after margin adjustment, and most features exhibited the same trend of variation in all three SUV maps. As expected, the performance of 'First order_Maximum' remained basically the same after margin adjustment, and 2 of the 31 distinguishing features from the SUV map performed worse than 'First order_Maximum' after margin adjustment, while 6 new better features were identified. The fluctuation of performance in radiomics features was larger in the SUV/ncc and SUV/nbm maps than in SUV map, and there were also greater number of newly identified features with the two calibrated maps. Features that performed better than 'First order_Maximum' were also ranked by AUC values from each of the three radiomics maps before and after margin adjustment to demonstrate stability, and the rankings are displayed in Supplementary material 3.

3.4. Analysis for solid metabolic tumors {#s0090}
----------------------------------------

The differentiation performance of most radiomics features for solid metabolic tumors had minimal variation compared with that for the whole population, although the number of distinguishing features decreased by 6, 6, and 1 from the SUV map, SUV/ncc map, and SUV/nbm map, respectively. In accordance with the findings in the whole population, most features remained stable after margin adjustment. The heat map of the 25 distinguishing features from the SUV map is shown in [Fig. 2](#f0010){ref-type="fig"}(C). The statistical properties and differentiation performances for solid metabolic tumors are shown in [Supplementary material 4](#ec0020){ref-type="supplementary-material"}. Features that had better differentiation performance than 'First order_Maximum' for solid metabolic tumors are displayed in [Fig. 3](#f0015){ref-type="fig"}. The rankings of features before and after margin adjustment are detailed in Supplementary material 5.

3.5. Feature selection and performance evaluation {#s0095}
-------------------------------------------------

Among the 107 involved radiomics features, 95 were significantly different between GBM and lymphoma (*p* \< 0.05), 46 were relatively stable after marginal adjustment (ICC \> 0.50), and 15 outperformed 'First order_Maximum' in all of the 12 abovementioned circumstances. Finally, 13 features that met the selection criteria were selected for the noninvasive differential diagnosis of lymphoma and GBM. In the SUV map, the selected radiomics features showed AUCs ranged from 0.971 to 0.998 in distinguish lymphoma and GBM in the whole population, and all of them demonstrated higher accuracy, sensitivity, specificity, precision rate and recall rate than 'First order_Maximum'. The discrimination performance of the selected radiomics features are displayed in [Table 2](#t0010){ref-type="table"}.Table 2The discrimination performance of the selected radiomics features in comparison with 'First order_Maximum'.Table 2Selected featuresAUCACCSENSPEPRERECICCFirst order_90 percentile0.9840.9480.9430.9580.9800.9430.793First order_Mean0.9800.9480.9620.9170.9620.9620.803First order_Median0.9770.9480.9620.9170.9620.9620.792First order_Root mean squared0.9840.9610.9810.9170.9630.9810.807GLCM_Contrast0.9860.9480.9620.9170.9620.9620.593GLCM_Difference average0.9900.9480.9430.9580.9800.9430.765GLCM_Difference entropy0.9760.9350.9620.8750.9440.9620.789GLCM_Difference variance0.9710.9090.9060.9170.9600.9060.580GLCM_Inverse difference0.9910.9350.9061.0001.0000.9060.811GLCM_Inverse difference moment0.9910.9350.9061.0001.0000.9060.819GLRLM_Run length non-uniformity normalized0.9980.9740.9621.0001.0000.9620.835GLRLM_Run percentage0.9910.9740.9810.9580.9810.9810.793GLDM_Large dependence emphasis0.9870.9740.9810.9580.9810.9810.724First order_Maximum (comparison)0.9430.8830.8870.8750.9400.8870.716[^3]

3.6. Feature validation with machine learning approach {#s0100}
------------------------------------------------------

The cross-validated AUC values of the 'First order_Maximum' ranged from 0.690 to 0.815 in all of the 6 circumstances with the whole population, which were lower than AUCs without cross-validation. Most of the 13 selected radiomics features displayed a cross-validated AUCs higher than that of the 'First order_Maximum' but also lower than their original AUCs. The 13 features displayed cross-validated AUCs ranging from 0.784 to 0.969 in the SUVmap in the differential diagnosis with the whole population. The cross-validated AUCs of the selected radiomics features with the whole population under the 6 circumstances are presented in [Table 3](#t0015){ref-type="table"}.Table 3The area under curve values based on cross validation in six circumstances with whole population.Table 3Selected featuresTT.nccT.nbmT.maT.ma.nccT.ma.nbmFirst order_90 percentile0.8500.9410.9670.9290.8010.829First order_Mean0.8330.7570.8780.7500.9000.857First order_Median0.9690.8010.9440.8570.8000.900First order_Root mean squared0.9380.7400.9550.8000.8210.889GLCM_Contrast0.8930.7051.0000.8640.8470.875GLCM_Difference average0.9170.7140.9690.9580.7171.000GLCM_Difference entropy0.8570.7950.9670.8570.8780.964GLCM_Difference variance0.7840.9580.9290.8750.7810.917GLCM_Inverse difference0.9550.9170.8290.9290.8150.892GLCM_Inverse difference moment0.8570.7020.8640.9000.7500.839GLRLM_Run length non-uniformity normalized0.9640.8331.0000.9690.8330.962GLRLM_Run percentage0.9551.0000.8570.9640.8000.900GLDM_Large dependence emphasis0.9290.9000.9001.0000.9000.889First order_Maximum (comparison)0.7500.6900.8150.7500.7390.762[^4]

3.7. Differentiation presentation {#s0105}
---------------------------------

One lymphoma and one GBM patient who shared similar metabolic types of tumors and had comparable SUVmax values were selected for discrimination using radiomics maps. The radiomics maps of these two patients are demonstrated in [Fig. 4](#f0020){ref-type="fig"}. The selected features, discrimination threshold values, and values of the selected features in these two patients are detailed in [Table 4](#t0020){ref-type="table"}.Fig. 4Radiomics maps of the selected radiomics features in a lymphoma patient (A) and a glioblastoma patient (B). First order features demonstrated a higher SUV in the region of interest and the texture features displayed a more mathematically heterogeneous of lymphomas. Although the radiomics maps presented here are different from what have been calculated in radiomics feature analysis, they provide an intuitive way for visualization.Fig. 4Table 4Selected radiomics features, their discrimination performances and threshold value.Table 4Selected featuresThresholdValues of two specific patientsLymphomaGlioblastomaPerformanceFirst order_90 percentile11.7214.5110.81AccurateFirst order_Mean8.38012.127.508AccurateFirst order_Median8.17111.987.236AccurateFirst order_Root mean squared9.43012.247.822AccurateGLCM_Contrast1.1261.1670.7556AccurateGLCM_Difference average0.7470.76720.5762AccurateGLCM_Difference entropy1.5001.5041.313AccurateGLCM_Difference variance0.4840.54630.4126AccurateGLCM_Inverse difference0.6860.67630.7396AccurateGLCM_Inverse difference moment0.6700.65610.7298AccurateGLRLM_Run length non-uniformity normalized0.5080.51740.3889AccurateGLRLM_Run percentage0.6510.65550.5280AccurateGLDM_Large dependence emphasis122.4121.8205.2Accurate[^5]

4. Discussion {#s0110}
=============

Our study demonstrated the distinguishing characteristics of CNS lymphoma and GBM on ^18^F-FDG-PET in addition to SUVmax through a radiomics approach. An SUV map, SUV/ncc map, and SUV/nbm map were generated to test the effectiveness of different correction techniques, and 107 radiomics features were extracted from each SUV map. The performance of each radiomics feature was evaluated, and margin adjustments were performed to evaluate the feature stability both in numeric value and in prediction performance. Analysis of solid metabolic tumors was also performed. Ultimately, 13 radiomics features were selected, revealing the discriminating characteristics of CNS lymphoma and GBM on ^18^F-FDG-PET and providing a dependable approach for noninvasive differential diagnosis of CNS lymphoma from GBM.

^18^F-FDG-PET has proven to be a reliable clinical diagnostic tool for CNS lymphoma and GBM. Previous studies on the differentiation of CNS lymphoma from GBM mainly utilized quantitative parameters such as SUVmax or the T/N ratio and reached an AUC of approximately 0.90([@bb0170]; [@bb0130]; [@bb0185]). Our study demonstrated a similar result, with AUC of SUVmax reached 0.943 and AUC of the T/N ratio reached 0.870 using a single feature threshold-based simple classifier (consistent with previous studies). However, these two parameters only reflect limited (although representative) information regarding the whole tumor, and the diagnostic performance can be further improved if the imaging characteristics of the tumor are comprehensively investigated. The current study explored the distinguishing role of shape, first-order and texture features on ^18^F-FDG-PET using a radiomics approach and selected 13 distinguishing radiomics features. Each single selected radiomics feature displayed excellent discrimination performance, reaching an AUC of 0.971--0.998 in the whole population and 0.977--1.00 in solid metabolic tumors, and this outstanding performance weakened the needs for establishing a mathematic model that combines the selected features together to achieve better performance than each individual feature. As a comparison, previous studies based on multiparametric MRI radiomics (including conventional MRI sequences and advanced MRI sequences) to differentiate CNS lymphoma from GBM selected radiomics features and built mathematic models, and these models reached AUCs ranging from 0.877--0.956 (not superior to all of the single selected ^18^F-FDG-PET radiomics features)([@bb0175]; [@bb0005]; [@bb0070]; [@bb0040]; [@bb0140]; [@bb0060]), suggesting the dependability of ^18^F-FDG-PET radiomics for differentiating CNS lymphoma from GBM. In addition to the higher AUC values, the 13 selected features also demonstrated higher performances in alternative evaluating indicators (e.g., accuracy, sensitivity, specificity, precision rate and recall rate), which illustrates the balance and reliability of these features. The selected features were also validated using a machine learning approach, and most of their cross-validated AUCs were higher than that of the 'First order_Maximum', indicating an insignificant overfitting of the final features. It is also worth noting that despite the considerable differences in solid metabolic tumors and cystic metabolic tumors recognized by the naked eye, there was a high degree of coincidence in the distinguishable features in the whole population and in solid metabolic tumors, suggesting the capability of the radiomics approach to differentiate CNS lymphoma and GBM regardless of metabolic patterns. Nevertheless, ^18^F-FDG-PET has a relatively lower resolution than conventional MRI and the Gaussian convolution filter, which is a part of the standard protocol in the reconstruction of PET image, unsharps the details of the images. Taking the loss of information when resampling into consideration, no resampling was carried out in order to maintain the relatively higher resolution. In addition, features from specific frequency domains in ^18^F-FDG-PET may be inaccurate, and therefore, wavelet features were excluded in our study.

In general, radiomics features extracted from the SUV map performed the best compared to the features extracted from the SUV/ncc and SUV/nbm maps, although it did least in calibrating differences among patients. Features from the SUV/ncc map displayed acceptable but lower discrimination performance than features derived from the SUV/nbm map, suggesting that normal contralateral cortex activity may not be the most accurate parameter for correction in radiomics studies. An unavoidable shortcoming of the additional calibration of the SUV map is the reduction in the dynamic range of the map. Since the calibration factor (e.g., ncc or nbm in our study) is usually \>1.0, each pixel would have lower values after calibration, leading to a decrease in matrix resolution and fewer details presented by radiomics features. Since the generation of SUV has experienced a number of corrections, additional calibration may be unnecessary in CNS ^18^F-FDG-PET radiomics studies.

The accuracy of most radiomics features relies on precise segmentation of the tumor, yet manual segmentations may have minor inaccuracies at the edges of the ROI, and stability of radiomics features were measured through marginal adjustment. Marginal expansion of 2 voxels (2 mm in X-Y plane and 3 mm in the Z axis) was chosen because it was a possible distance with a temperate size considering the resolution of the DICOM data. Features that were distinguishable in all of the 12 circumstances but numeric unstable after marginal adjustment (e.g., 'GLRLM_Long run low grey level emphasis') were excluded during the final selection of features since the significant influence of margin to feature value may affect the settlement of cutoff value and thereby restrict their clinical application, and the mean ICC of the final selected features reached 0.761, demonstrating a good intraclass agreement. Features that were numeric stable but not distinguishable in all circumstances (e.g., 'First order_10 percentile') were also excluded due to the inter-reader discrepancy of segmentations. Interestingly, the number of distinguishable features increased after margin adjustment regardless of the calibration method or analyzed population, suggesting that the peri-tumor area may also contain information that can distinguish CNS lymphoma and GBM. Radiomics features in such peri-tumor area as well as the intratumoral habitat regions from multimodal imaging may provide additional information about tumor properties, and the biological processes underlying these imaging features remains to be investigated([@bb0155]; [@bb0160]; [@bb0025]; [@bb0165]).

First-order features refer to imaging characteristics exhibited by voxels alone. In addition to 'First order_Maximum', the '90 percentile', '10 percentile', 'Mean', 'Median', 'Root mean squared' of the SUV values in ROIs can also distinguish CNS lymphoma from GBM (both in the whole population and in patients with solid metabolic tumors), suggesting a higher SUV of most interval segments of lymphomas no matter the metabolic patterns. Although lymphoma is typically considered to have a uniform metabolic pattern compared with glioma, this characteristic may have less discriminatory capacity because the first order features that are relevant to distribution deviation (e.g., 'Skewness', 'Kurtosis', 'Skewness', 'Variance') did not surpass 'First order_Maximum'. Texture features refer to the presentation of textures exhibited by special defined grey level matrices, and each type of grey level matrix reflects certain aspects of the image, including the relationships to the adjacent voxel, voxel blocks and linear scales. The grey level cooccurrence matrix (GLCM) expresses the distribution of neighboring voxels, and 6 of all the 13 selected features were derived from the GLCM, with 'GLCM_Contrast' measures the local intensity variation, 'GLCM_Difference average', 'GLCM_Entropy' and 'GLCM_Variance' describe the differences in neighborhood intensity, and 'GLCM_Inverse difference' and 'GLCM_Inverse difference moment' measure the local homogeneity. These 6 GLCM features indicated that GBM had more homogeneity and lower contrast adjacent voxel relationships than lymphoma did (note: the 'homogeneity' here is supported by the value of radiomics features calculated directly from the pixels of SUV maps instead of the ratio of pixels to a certain threshold \[e.g., SUVmax\], which is more favorable for judgment made by the naked eye). Two selected features were derived from the grey level run length matrix (GLRLM), which counts the maximum length of voxels with identical grey levels in a certain direction. 'GLRLM_Run length non-uniformity normalized' measures the similarity of run lengths, and 'GLRLM_Run percentage' illustrates the coarseness of textures. The final selected feature was derived from grey level dependence matrix (GLDM), which is constructed with a given distance and calculated based on the center voxel. The differences in these 3 GLRLM and GLDM derived features also suggested that GBM was more uniform and homogeneous than lymphoma. It is also worth mentioning that alternative GLRLM features (e.g., 'GLRLM_Short run emphasiss') are also numeric stable and outperformed 'First order_Maximum' in 11 of the 12 situations and may also be included for distinguishing lymphoma from GBM. On the other hand, shape features and other texture features (features from the grey level size zone matrix and neighboring grey tone difference matrix) may not be distinguishing characteristics compared with 'First order_Maximum'.

The current study has a few limitations. First, the patient population included in this study was relatively small, and ^18^F-FDG-PET examination is not mandatory in patients with CNS diseases, both of which may have introduced selection bias. The limited number of patients also prevented validation with an independent cohort to assess our findings, and further large-scale prospective studies are needed. Second, the study was performed without information regarding post therapy changes due to the variations in therapeutic principles and regimens, and more comprehensive clinical data are needed to discover the prognostic values of the current findings. Third, in addition to GBM, CNS lymphomas may need to differentiate with other CNS malignancies (e.g., high grade astrocytoma or oligodendroglioma with contrast-enhancement on MRI and solid metabolic pattern on ^18^F-FDG-PET) or alternative CNS disorders (e.g., infection, inflammation or demyelination), and further study for noninvasive differentiation may be carried out. And finally, despite the good discriminating capacities of the selected features, the biological processes that underlie these features remains to be understood.

5. Conclusions {#s0115}
==============

^18^F-FDG-PET-based radiomics provides a reliable noninvasive method for distinguishing CNS lymphoma from GBM. Several stable and highly discriminative first-order and texture features suggest that lymphoma has a higher SUV in most interval segments and is more mathematically heterogeneous than GBM.
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